UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease

Clinical and applied thrombosis/hemostasis, 2006-10, Vol.12 (4), p.397-420

2006

Volltextzugriff (PDF)

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis

European heart journal, 2005-03, Vol.26 (6), p.567-575

2005

Volltextzugriff (PDF)

Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic Implications

Seminars in thrombosis and hemostasis, 2006-04, Vol.32 (3), p.174-207

2006

Volltextzugriff (PDF)

Multiplate whole blood impedance aggregometry: a recent experience

Thrombosis and haemostasis, 2008-10, Vol.100 (4), p.725-726

2008

Volltextzugriff (PDF)

Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation

Thrombosis research, 2003, Vol.111 (3), p.159-164

2003

Volltextzugriff (PDF)

Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: Experience with the point-of-care Platelet Function Assay–100 C/ADP

The American heart journal, 2010-03, Vol.159 (3), p.434-438

2010

Volltextzugriff (PDF)

Characterization, Classification, and Treatment of von Willebrand Diseases: A Critical Appraisal of the Literature and Personal Experiences

Seminars in thrombosis and hemostasis, 2005-11, Vol.31 (5), p.577-601

2005

Volltextzugriff (PDF)

Intravenous DDAVP and Factor VIII-von Willebrand Factor Concentrate for the Treatment and Prophylaxis of Bleedings in Patients With von Willebrand Disease Type 1, 2 and 3

Clinical and applied thrombosis/hemostasis, 2007-01, Vol.13 (1), p.14-34

2007

Volltextzugriff (PDF)

Platelet Prothrombinase Activity, a Final Pathway Platelet Procoagulant Activity, Is Overexpressed in Type 1 Diabetes: No Relationship With Mean Platelet Volume or Background Retinopathy

Clinical and applied thrombosis/hemostasis, 2000-04, Vol.6 (2), p.65-68

2000

Volltextzugriff (PDF)

Identification of a novel candidate splice site mutation (0874 + 1G > A) in a type 3 von Willebrand disease patient

Thrombosis and haemostasis, 2007-08, Vol.98 (2), p.464-466

2007

Volltextzugriff (PDF)

Relationship between histologic chorioamnionitis and early inflammatory variables in blood, tracheal aspirates, and endotracheal colonization in preterm infants

Pediatric research, 2003-07, Vol.54 (1), p.113-119

2003

Volltextzugriff (PDF)

Acquired von Willebrand Syndrome Type 1 in Hypothyroidism: Reversal After Treatment With Thyroxine

Clinical and applied thrombosis/hemostasis, 2001-04, Vol.7 (2), p.113-115

2001

Volltextzugriff (PDF)

Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWD

Clinical and applied thrombosis/hemostasis, 2006-07, Vol.12 (3), p.277-295

2006

Volltextzugriff (PDF)

Influence of academic examination stress on hematological measurements in subjectively healthy volunteers

Psychiatry research, 1998-09, Vol.80 (3), p.201-212

1998

Volltextzugriff (PDF)

Guidelines for the Evaluation of Intravenous Desmopressin and von Willebrand Factor/Factor VIII Concentrate in the Treatment and Prophylaxis of Bleedings in von Willebrand Disease Types 1, 2, and 3

Seminars in thrombosis and hemostasis, 2006-09, Vol.32 (6), p.636-645

2006

Volltextzugriff (PDF)

Atypical Variant of Acquired von Willebrand Syndrome in Wilms Tumor: Is Hyaluronic Acid Secreted by Nephroblastoma Cells the Cause?

Clinical and applied thrombosis/hemostasis, 2001-04, Vol.7 (2), p.102-105

2001

Volltextzugriff (PDF)

Acquired von Willebrand Syndrome in Systemic Lupus Erythematodes

Clinical and applied thrombosis/hemostasis, 2001-04, Vol.7 (2), p.106-112

2001

Volltextzugriff (PDF)

Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin?

European journal of endocrinology, 2006-09, Vol.155 (3), p.477-484

2006

Volltextzugriff (PDF)

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management

Best practice & research. Clinical haematology, 2001-06, Vol.14 (2), p.401-436

2001

Volltextzugriff (PDF)

Haemostatic changes and acquired activated protein C resistance in normal pregnancy

Blood coagulation & fibrinolysis, 2007-10, Vol.18 (7), p.685-688

2007

Volltextzugriff (PDF)

Dominant von Willebrand Disease Type 2M and 2U Are Variable Expressions of One Distinct Disease Entity Caused by Loss-of-Function Mutations in the A1 Domain of the von Willebrand Factor Gene

Acta haematologica, 2009-01, Vol.121 (2-3), p.145-153

2009

Volltextzugriff (PDF)

Immune-Mediated Etiology of Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus and in Benign Monoclonal Gammopathy: Therapeutic Implications

Seminars in thrombosis and hemostasis, 2006-09, Vol.32 (6), p.577-588

2006

Volltextzugriff (PDF)

Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?

Metabolism, clinical and experimental, 2006-05, Vol.55 (5), p.650-655

2006

Volltextzugriff (PDF)

Laboratory and Molecular Characteristics of Recessive von Willebrand Disease Type 2C (2A Subtype IIC) of Variable Severity due to Homozygous or Double Heterozygous Mutations in the D1 and D2 Domains

Acta haematologica, 2009-01, Vol.121 (2-3), p.111-118

2009

Volltextzugriff (PDF)

Routine Measurement of Endogenous Thrombin Potential (ETP) To Assess Hemostatic Function in Patients with Liver Cirrhosis

Blood, 2006-11, Vol.108 (11), p.4014-4014

2006

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

Humans
(39)
Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Biological And Medical Sciences
(25)
Hematology
(24)
Medical Sciences
(24)
Female
(22)
Male
(21)
Adult
(17)
Cardiovascular System & Cardiology
(17)
Middle Aged
(17)
Peripheral Vascular Disease
(16)
Aged
(13)
Fundamental And Applied Biological Sciences. Psychology
(12)
Hematologic And Hematopoietic Diseases
(12)
Platelet Diseases And Coagulopathies
(12)
Von Willebrand Factor
(11)
Bleeding Time
(10)
Von Willebrand Disease
(10)
Blood Coagulation. Blood Cells
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis

Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic Implications

Multiplate whole blood impedance aggregometry: a recent experience

Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation

Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: Experience with the point-of-care Platelet Function Assay–100 C/ADP

Characterization, Classification, and Treatment of von Willebrand Diseases: A Critical Appraisal of the Literature and Personal Experiences

Intravenous DDAVP and Factor VIII-von Willebrand Factor Concentrate for the Treatment and Prophylaxis of Bleedings in Patients With von Willebrand Disease Type 1, 2 and 3

Platelet Prothrombinase Activity, a Final Pathway Platelet Procoagulant Activity, Is Overexpressed in Type 1 Diabetes: No Relationship With Mean Platelet Volume or Background Retinopathy

Identification of a novel candidate splice site mutation (0874 + 1G > A) in a type 3 von Willebrand disease patient

Relationship between histologic chorioamnionitis and early inflammatory variables in blood, tracheal aspirates, and endotracheal colonization in preterm infants

Acquired von Willebrand Syndrome Type 1 in Hypothyroidism: Reversal After Treatment With Thyroxine

Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWD

Influence of academic examination stress on hematological measurements in subjectively healthy volunteers

Guidelines for the Evaluation of Intravenous Desmopressin and von Willebrand Factor/Factor VIII Concentrate in the Treatment and Prophylaxis of Bleedings in von Willebrand Disease Types 1, 2, and 3

Atypical Variant of Acquired von Willebrand Syndrome in Wilms Tumor: Is Hyaluronic Acid Secreted by Nephroblastoma Cells the Cause?

Acquired von Willebrand Syndrome in Systemic Lupus Erythematodes

Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin?

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management

Haemostatic changes and acquired activated protein C resistance in normal pregnancy

Dominant von Willebrand Disease Type 2M and 2U Are Variable Expressions of One Distinct Disease Entity Caused by Loss-of-Function Mutations in the A1 Domain of the von Willebrand Factor Gene

Immune-Mediated Etiology of Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus and in Benign Monoclonal Gammopathy: Therapeutic Implications

Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?

Laboratory and Molecular Characteristics of Recessive von Willebrand Disease Type 2C (2A Subtype IIC) of Variable Severity due to Homozygous or Double Heterozygous Mutations in the D1 and D2 Domains

Routine Measurement of Endogenous Thrombin Potential (ETP) To Assess Hemostatic Function in Patients with Liver Cirrhosis

Suchergebnisse filtern